Seize the Way

From listening to action – turning medical insights into patient impact

Author(s): Manuel Möller, Veeva Systems

Biopharma has never generated more data, more innovation or more scientific exchange.

Yet despite being one of the most valuable assets for improving patient outcomes, medical insights from the field remain underused.

The industry is facing a structural paradox. Breakthrough therapies are becoming more complex and targeted, but bringing them to market is slower, more expensive and more uncertain. Up to 90% of medicines that enter clinical development never reach the market.

In this environment, being able to understand real-world clinical need early and continuously is more than a competitive advantage, it is a necessity.

Medical affairs are at the centre of this opportunity. Through scientific exchange with key opinion leaders (KOLs), medical science liaisons (MSLs) capture frontline clinical insights that inform medical strategy, ensuring a therapy meets real-world patient needs.